Innova Captab Reports Strong Q1 FY27 Results: Revenue Jumps 34%, EBITDA Grows 32.7%

Innova Captab Reports Strong Q1 FY27 Results: Revenue Jumps 34%, EBITDA Grows 32.7%​

Innova Captab Limited, a leading pharmaceutical company committed to delivering high-quality healthcare solutions, announced its unaudited financial results for the quarter ended June 30, 2026. The company demonstrated robust performance across various metrics in Q1 FY27.

The consolidated financial summary highlights significant growth across key operational areas, as detailed below:

Q1FY27 Performance Metrics​

The results showcased strong growth compared to the previous year:

• Revenue from Operations grew by 34.0%, reaching ₹ 470.9 crores, up from ₹ 351.5 crores in Q1 FY26.
• EBITDA saw a substantial increase of 32.7% to ₹ 75.1 crores. The EBITDA margin for the quarter stood at 16.0%.
• Profit After Tax (PAT) registered growth of 42.3%, amounting to ₹ 44.1 crores, with a PAT margin of 9.4%.

Management Commentary on Business Performance​

Mr. Vinay Lohariwala, Managing Director of Innova Captab Limited, commented on the results, stating that the company delivered a strong start to FY27. He attributed this performance to the sustained strength of its diversified business model and disciplined execution across both CDMO Services and Branded Generics businesses.

"The performance underscores the continued strength of our diversified business model," Lohariwala stated. "Growth during the quarter was supported by steady order flows, a broader product portfolio, and deeper engagement with existing and new customers."

He added that the company's focus on operational excellence and manufacturing efficiency is strengthening its competitive positioning. Furthermore, the Jammu facility is undergoing a steady ramp-up, bolstered by increased business from established clients and the addition of new clients. The management expressed confidence in sustaining growth while enhancing profitability across domestic and international markets.

Company Overview​

Innova Captab Limited is recognized as a leading pharmaceutical company in India, possessing a comprehensive business model that covers the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports.

The company operates through its Contract Development and Manufacturing Organization (CDMO) segment, providing elaborate pharmaceutical products to over 350 clients across India and international markets. Additionally, Innova Captab has a strong direct presence in both domestic and international markets via its Branded Generics business. The company manages five state-of-the-art manufacturing facilities that comprise nine independent blocks, accredited by leading global regulatory bodies such as WHO-GMP, EU-GMP, UK-MHRA, and PIC/s.

INNOVACAP Stock Price Movement​

Innova Captab Limited shares closed today by climbing 6.51%, successfully settling at ₹1018.9, after trading up from previous close of ₹966.1. The stock gained ₹62.90 on a volume of 167,241 shares and achieved a high of ₹1029 during the day's trading session.